Creative Medical Health Announces Creation Of Angiostem Inc. Subsidiary To Commercialize Issued Cardiovascular Stem Cell Patent

PHOENIX--(BUSINESS WIRE)--Creative Medical Health announced today formation of a subsidiary company, AngioStem Inc., dedicated to commercialization of its cardiovascular assets, including issued US patent #9,205,112, titled “Combination Therapy of Cardiovascular Disease.”

“The promise of stem cell therapeutics offers the possibility of specifically utilizing cells of the body to accelerate healing. At AngioStem the aim is to utilize stem cells to generate new blood vessels, which may be applicable to conditions ranging from heart failure, to peripheral artery disease, to stroke.”

The patent covers the use of autologous and allogeneic adult stem cells such as cord blood and mesenchymal stem cells in combination with modulation of oxidative stress in treatment of heart failure. Additionally, the patent covers in-treatment assessment of oxidative stress so as to give doctors the ability to personalize the treatment protocol to the particular needs of the patient.

“At Creative Medical Health, our mission is to identify promising technologies, add value by strengthening the science and intellectual property surrounding the technologies, and subsequently spin off new companies with specialized management teams,” said Timothy Warbington, President and Chief Executive Officer of Creative Medical Health. “The development of a business strategy, the successful acquisition of independent funding to implement the strategy, and the recruitment of a management team to lead the strategy have positioned our cardiac stem cell technology to evolve from a promising technology into a functioning corporation.”

Creative Medical Health owns a portfolio of technologies including an issued patent on use of autologous bone marrow stem cells for erectile dysfunction, currently in clinical trials, covered under patent #8,372,797 and a variety of regenerative technologies treating conditions including disc degeneration, male infertility, type 2 diabetes and multiple sclerosis.

“I look forward to working with the management team of AngioStem to bring stem cell technologies to patients who currently have no treatment options available,” said Dr. Amit N. Patel, Director of Regenerative Medicine and Tissue Engineering in the Department of Surgery at the University of Utah, and founding Board Member of Creative Medical Health. “The promise of stem cell therapeutics offers the possibility of specifically utilizing cells of the body to accelerate healing. At AngioStem the aim is to utilize stem cells to generate new blood vessels, which may be applicable to conditions ranging from heart failure, to peripheral artery disease, to stroke.”

“Utilizing the clinical translational expertise of Dr. Amit Patel, our previous company Medistem was successful at taking a stem cell product from bench to bedside, resulting in a successful exit for our investors. We intend to replicate the previous success at AngioStem,” said Thomas Ichim, Ph.D., Founding Board Member of Creative Medical Health and President and Chief Executive Officer of AngioStem.